Comparison between CNS-ICI and PN-ICI
| Features | CNS-ICI (N=19; present series) | PN-ICI (N=77; review of the literature)* | P value |
| Tumours, n (%) | |||
| Melanoma | 3 (16) | 56 (73) | <0.01 |
| NSCLC | 8 (42) | 10 (13) | <0.01 |
| Others | 8 (42) | 11 (14) | 0.01 |
| Type of ICI, n (%) | 0.01 | ||
| Anti-CTLA4 alone | 0 | 20 (26) | |
| Others | 19 (100) | 57 (74) | |
| Ab status, n (%) | <0.01 | ||
| Ab+ | 11 (58) | 8 (10)† | |
| Ab− | 8 (42) | 69 (90) | |
| Outcome, n (%) | 0.053 | ||
| Worsened/died | 7 (37) | 12 (16) | |
| Stable/improved | 12 (63) | 65 (84) |
*Online supplementary references 1−37.
†Ab+ included 1 GM2+GD1a; 1 GM1; 1 NS6S+TS-HDS; 1 MPO+PR3; 1 pANCA; 1 P/Q VGCC; 1 Striatal Abs; 1 novel (IgM against myelinating sensory neurons and Schwann cells).
Ab, antibody; CNS-ICI, central nervous system immune-related complications; CTLA4, cytotoxic T-lymphocyte antigen 4; ICI, immune checkpoint inhibitor; NSCLC, non-small cell lung cancer; PN-ICI, peripheral neuropathies triggered by ICIs.